Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.1K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

373
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
373

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulating Surface Overpotential for Uniform Zinc Stripping/Plating Morphology Toward Ultra-Stable Aqueous Zinc-Ion Batteries.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

The genetic repertoire of deep-sea microbiome: From sequence to structure and function.

Cell host & microbe·2026
Same author

First detection of human adenovirus type 7 deletion mutant associated with an outbreak of acute respiratory infection.

Virology journal·2026
Same author

Gut-brain axis crosstalk in patients with Alzheimer's disease and high body mass index: Gut dysbiosis, blood-brain barrier disruption, and neuroinflammation.

Journal of Alzheimer's disease : JAD·2026
Same author

Evaluating place cell detection methods in Rats and Humans: Implications for cross-species spatial coding.

PLoS computational biology·2026
Same author

Isolation and Transcriptomic Characterization of Genotype 5 Japanese Encephalitis Virus E138K Mutant Strain.

Transboundary and emerging diseases·2026
Same journal

Correction: A method for supervoxel-wise association studies of age and other non-imaging variables from coronary computed tomography angiograms.

Scientific reports·2026
Same journal

Poly(bromophenol blue)/CoSn(OH)<sub>6</sub> cubic particles modified pencil graphite electrode for electrochemical determination of diphenhydramine.

Scientific reports·2026
Same journal

Dietary Chlorella, Spirulina, and acidifier modulate jejunal cytokine-related gene expression in broiler chickens.

Scientific reports·2026
Same journal

Perceived physical activity barriers in university students: associations with fatigue and eating behaviours.

Scientific reports·2026
Same journal

Refuge limitation structures habitat use in agricultural landscapes: evidence from Sunda pangolins.

Scientific reports·2026
Same journal

Lightweight stateless transaction verification with outsourced witness updates for UTXO blockchains.

Scientific reports·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.6K

A new function for drug combination dose finding trials.

Jiacheng Xiao1, Weijia Zhang2

  • 1Department of Financial and Actuarial Mathematics, Xi'an Jiaotong-Liverpool University, Suzhou, 215123, Jiangsu, China.

Scientific Reports
|February 12, 2024
PubMed
Summary
This summary is machine-generated.

This study introduces a new method for finding optimal doses in cancer combination drug trials. The novel approach improves efficiency and accuracy in dose escalation and de-escalation, aiding treatment strategies.

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.8K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K

Related Experiment Videos

Last Updated: Jul 3, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.6K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.8K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K

Area of Science:

  • Oncology
  • Biostatistics
  • Clinical Trial Design

Background:

  • Combination drugs are crucial for cancer treatment.
  • Determining optimal dose-toxicity ordering for combination therapies presents a significant challenge.
  • Pre-determining dose escalation and de-escalation sequences is essential for effective dose-finding.

Purpose of the Study:

  • To extend the continual reassessment method (CRM) for drug-combination dose-finding trials.
  • To incorporate a normal distribution function within the CRM framework for enhanced dose selection.
  • To systematically evaluate the performance of the novel method using established metrics.

Main Methods:

  • Developed a novel CRM function integrating normal distribution for combination drug trials.
  • Utilized nearest neighborhood CRM principles for dose escalation and de-escalation rules.
  • Specified all potential dose-toxicity orderings within the trial design.
  • Evaluated performance using the EARS (Efficiency, Accuracy, Reliability, Selection) template.

Main Results:

  • The new design demonstrated high efficiency in dose-finding.
  • The method proved to be accurate in identifying appropriate dose levels.
  • Simulations indicated that the approach is reasonably reliable for clinical application.

Conclusions:

  • The extended CRM offers an efficient and accurate approach for dose-finding in cancer combination drug trials.
  • The method provides a reliable framework for managing dose escalation and de-escalation.
  • This novel design aids in specifying dose-toxicity ordering, advancing treatment strategies.